Ropes & Gray Advises Novo Nordisk in Collaboration With IMMvention Therapeutix to Co-Develop Oral Therapies for Sickle Cell Disease
January 24, 2025
January 24, 2025
BOSTON, Massachusetts, Jan. 24 -- Ropes and Gray, a law firm, issued the following news:
Ropes & Gray represented Novo Nordisk in a strategic collaboration and license agreement with IMMvention Therapeutic to develop oral therapies for sickle cell disease and other chronic conditions.
The collaboration was announced on January 22. Financial terms were not disclosed.
The companies will jointly advance IMMvention's portfolio of preclinical BACH1 inhi . . .
Ropes & Gray represented Novo Nordisk in a strategic collaboration and license agreement with IMMvention Therapeutic to develop oral therapies for sickle cell disease and other chronic conditions.
The collaboration was announced on January 22. Financial terms were not disclosed.
The companies will jointly advance IMMvention's portfolio of preclinical BACH1 inhi . . .